Health Economics›Acute myeloid leukemia pediatric›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Acute myeloid leukemia pediatric · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG AAML1421 protocol N/A - intrathecal component Partial	—	R 55 619	28d	—	—	~1	~R 55 619 indirect	—
FLAG Variant #01	—	R 47 479	—	—	~6.7 mo	~2	~R 94 958 PFS proxy · indirect	1
FLAG-DNX Variant #01 Partial	—	R 47 479	—	—	—	~2	~R 94 958 indirect	—

3 of 3 regimens shown